AUPH

Aurinia Pharmaceuticals Inc

$14.86

-0.33 (-2.17%)

quotes and stock data delayed 15 minutes

52 wk hi

52 wk low

11.34

20.37

Cash

$392M

Burn Rate (Qtr)

$34.1M

Mkt Cap

$1.9b

Avg Volume

3,814,933

*cash/burn updated:

Q3 '20

Company Profile

Aurinia is a clinical stage biopharmaceutical company focused on developing and commercializing therapies in disease areas of high unmet medical need. We are currently developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN) and focal segmental glomerularsclerosis (FSGS). Additionally, we are advancing voclosporin ophthalmic solution (VOS), a topical formulation, for the treatment of dry eye syndrome (DES).

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

Voclosporin

Lupus Nephritis

PDUFA

Jan 22, 2021

Approval Decision

7/22/2020 FDA accepted NDA filing and granted priority review - PDUFA set for 1/22/21

Voclosporin

FSGS (Focal Segmental Glomerulosclerosis)

Discontinued

Voclosporin Ophthalmic Solution

Dry Eye Syndrome